Advances in Cancer Biology - Metastasis Исследования рака

Suppression of medulloblastoma by TLR9 activation

Daniela Melissa Abarca-Merlin, Jocelyn Abigail Martínez-Durán, Pablo Domínguez-López, Carmen Maldonado-Bernal, Lourdes Alvarez-Arellano
Elsevier · · DOI 10.2139/ssrn.6881178

Аннотация

Medulloblastoma is an embryonal tumor that develops in the cerebellum and mainly affects children. In recent years, progress has been made towards understanding the pathological, genetic, and molecular heterogeneity of medulloblastomas; however, as solid tumors grow in an extraordinarily complex microenvironment, further research on their risk classification, prognosis, and treatment is needed. Multiple factors related to tumor pathophysiology, including the immune system, influence tumor growth and the response to chemotherapy. Toll-like receptor agonists have been used, alone or in combination with conventional treatments, to increase tumor chemosensitivity and prolong survival in cancer patients. However, these aspects remain unexplored in the context of medulloblastoma. The present study aimed to determine the effects of administering the synthetic ligands for TLR7 and TLR9 on the development of medulloblastoma. We administered intratumorally synthetic oligonucleotide (ODN1826) or resiquimod (R848) into established subcutaneous xenograft in nu/nu immunodeficient mice and examined their effects on tumor cell proliferation, apoptotic cell death and vascularization. Our results demonstrate that activating TLR9 with ODN1826 decreases tumor volume and tumor cell proliferation, inhibits vascularization, and slightly promotes tumor cell apoptosis. These results hold promise for the treatment of medulloblastomas.

Читать у издателя →